Ultra-Long-Acting Oral Antipsychotic for Treatment of Schizophrenia
A new phase II study suggested improved quality of life and treatment adherence in schizophrenic patients with a novel, ultra-long-acting formulation of risperidone (LYN-005). The study comprised of 32 schizophrenia patients received immediate-release (IR) risperidone 2 mg or 4 mg and were randomized to either of the four groups, IR risperidone-matched placebo and LYN-005 at […]